Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galcanezumab, an antibody targeting CGRP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fremanezumab, an antibody targeting CGRP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Evolocumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Alirocumab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Evinacumab, an antibody targeting ANGPTL3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Emapalumab, an antibody targeting IFN-γ.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Satralizumab, an antibody targeting IL-6R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teplizumab, an antibody targeting CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teprotumumab, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Margetuximab, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pertuzumab, an antibody targeting HER2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trastuzumab, an antibody targeting HER2.